{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T06:39:11Z","timestamp":1717742351993},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,3,9]],"date-time":"2020-03-09T00:00:00Z","timestamp":1583712000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,3,9]],"date-time":"2020-03-09T00:00:00Z","timestamp":1583712000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics Open"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s41669-020-00205-y","type":"journal-article","created":{"date-parts":[[2020,3,9]],"date-time":"2020-03-09T05:03:08Z","timestamp":1583730188000},"page":"649-655","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Application of a Mapping Function to Estimate Utilities for Ragweed Allergy Immunotherapy Trials"],"prefix":"10.1007","volume":"4","author":[{"given":"Katherine","family":"Dick","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Briggs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henrik","family":"Brandi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,3,9]]},"reference":[{"issue":"3\u20134","key":"205_CR1","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1159\/000487997","volume":"176","author":"KW Chen","year":"2018","unstructured":"Chen KW, et al. Ragweed Pollen Allergy: burden, Characteristics, and Management of an Imported Allergen Source in Europe. Int Arch Allergy Immunol. 2018;176(3\u20134):163\u201380.","journal-title":"Int Arch Allergy Immunol"},{"issue":"5","key":"205_CR2","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1016\/j.jaci.2010.12.1106","volume":"127","author":"PM Salo","year":"2011","unstructured":"Salo PM, et al. Allergy-related outcomes in relation to serum IgE: results from the National Health and Nutrition Examination Survey 2005\u20132006. J Allergy Clin Immunol. 2011;127(5):1226\u201335 (e7).","journal-title":"J Allergy Clin Immunol"},{"key":"205_CR3","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.envint.2013.08.005","volume":"61","author":"M Smith","year":"2013","unstructured":"Smith M, et al. Common ragweed: a threat to environmental health in Europe. Environ Int. 2013;61:115\u201326.","journal-title":"Environ Int"},{"issue":"10","key":"205_CR4","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1111\/j.1398-9995.2009.02089.x","volume":"64","author":"GJ Burbach","year":"2009","unstructured":"Burbach GJ, et al. GA(2)LEN skin test study II: clinical relevance of inhalant allergen sensitizations in Europe. Allergy. 2009;64(10):1507\u201315.","journal-title":"Allergy"},{"issue":"1","key":"205_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/ACI.0b013e3282f3f42f","volume":"8","author":"E Valovirta","year":"2008","unstructured":"Valovirta E, Myrseth SE, Palkonen S. The voice of the patients: allergic rhinitis is not a trivial disease. Curr Opin Allergy Clin Immunol. 2008;8(1):1\u20139.","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"4","key":"205_CR6","doi-asserted-by":"publisher","first-page":"235","DOI":"10.2500\/ajra.2017.31.4444","volume":"31","author":"LP Hoehle","year":"2017","unstructured":"Hoehle LP, et al. Association between symptoms of allergic rhinitis with decreased general health-related quality of life. Am J Rhinol Allergy. 2017;31(4):235\u20139.","journal-title":"Am J Rhinol Allergy"},{"key":"205_CR7","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12948-016-0049-9","volume":"14","author":"A Linneberg","year":"2016","unstructured":"Linneberg A, et al. Burden of allergic respiratory disease: a systematic review. Clin Mol Allergy. 2016;14:12.","journal-title":"Clin Mol Allergy"},{"issue":"1","key":"205_CR8","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1076\/opep.11.1.17.26437","volume":"11","author":"AD Pitt","year":"2004","unstructured":"Pitt AD, et al. Economic and quality-of-life impact of seasonal allergic conjunctivitis in Oxfordshire. Ophthalmic Epidemiol. 2004;11(1):17\u201333.","journal-title":"Ophthalmic Epidemiol"},{"issue":"1","key":"205_CR9","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.drudis.2015.07.010","volume":"21","author":"JN Larsen","year":"2016","unstructured":"Larsen JN, Broge L, Jacobi H. Allergy immunotherapy: the future of allergy treatment. Drug Discov Today. 2016;21(1):26\u201337.","journal-title":"Drug Discov Today"},{"issue":"3","key":"205_CR10","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1136\/adc.2010.183095","volume":"96","author":"A Fiocchi","year":"2011","unstructured":"Fiocchi A, Fox AT. Preventing progression of allergic rhinitis: the role of specific immunotherapy. Arch Dis Child Educ Pract Ed. 2011;96(3):91\u2013100.","journal-title":"Arch Dis Child Educ Pract Ed"},{"issue":"3","key":"205_CR11","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1016\/j.jaci.2018.12.1001","volume":"143","author":"T Biedermann","year":"2019","unstructured":"Biedermann T, et al. The SQ tree SLIT-tablet is highly effective and well tolerated: results from a randomized, double-blind, placebo-controlled phase III trial. J Allergy Clin Immunol. 2019;143(3):1058\u201366.","journal-title":"J Allergy Clin Immunol"},{"issue":"11","key":"205_CR12","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1111\/all.13201","volume":"72","author":"S Dhami","year":"2017","unstructured":"Dhami S, et al. Allergen immunotherapy for allergic rhinoconjunctivitis: a systematic review and meta-analysis. Allergy. 2017;72(11):1597\u2013631.","journal-title":"Allergy"},{"key":"205_CR13","first-page":"253","volume":"4","author":"SM Ronborg","year":"2012","unstructured":"Ronborg SM, et al. Budget impact analysis of two immunotherapy products for treatment of grass pollen-induced allergic rhinoconjunctivitis. Clinicoecon Outcomes Res. 2012;4:253\u201360.","journal-title":"Clinicoecon Outcomes Res"},{"issue":"6","key":"205_CR14","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.jval.2016.06.001","volume":"19","author":"SE Wolowacz","year":"2016","unstructured":"Wolowacz SE, et al. Estimating health-state utility for economic models in clinical studies: an ISPOR Good Research Practices Task Force Report. Value Health. 2016;19(6):704\u201319.","journal-title":"Value Health"},{"issue":"3","key":"205_CR15","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.jval.2011.12.003","volume":"15","author":"MM Versteegh","year":"2012","unstructured":"Versteegh MM, et al. Condition-specific preference-based measures: benefit or burden? Value Health. 2012;15(3):504\u201313.","journal-title":"Value Health"},{"issue":"1","key":"205_CR16","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jval.2016.11.006","volume":"20","author":"AJ Wailoo","year":"2017","unstructured":"Wailoo AJ, et al. Mapping to estimate health-state utility from non-preference-based outcome measures: an ISPOR Good Practices for Outcomes Research Task Force Report. Value Health. 2017;20(1):18\u201327.","journal-title":"Value Health"},{"issue":"2","key":"205_CR17","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s10198-009-0168-z","volume":"11","author":"JE Brazier","year":"2010","unstructured":"Brazier JE, et al. A review of studies mapping (or cross walking) non-preference based measures of health to generic preference-based measures. Eur J Health Econ. 2010;11(2):215\u201325.","journal-title":"Eur J Health Econ"},{"issue":"1","key":"205_CR18","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1080\/13696998.2019.1649268","volume":"23","author":"K Dick","year":"2019","unstructured":"Dick K, et al. A quality of life mapping function developed from a grass pollen sublingual immunotherapy trial to a tree pollen sublingual immunotherapy trial. J Med Econ. 2019;23(1):64\u20139.","journal-title":"J Med Econ."},{"issue":"3","key":"205_CR19","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.jaci.2011.12.973","volume":"129","author":"SR Durham","year":"2012","unstructured":"Durham SR, et al. SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2\u00a0years after 3\u00a0years of treatment in a randomized trial. J Allergy Clin Immunol. 2012;129(3):717\u201325 (e5).","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"205_CR20","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.2147\/TCRM.S3544","volume":"4","author":"M Calder\u00f3n","year":"2008","unstructured":"Calder\u00f3n M, Brandt T. Treatment of grass pollen allergy: focus on a standardized grass allergen extract\u2014Grazax\u00ae. Ther Clin Risk Manag. 2008;4(6):1255\u201360.","journal-title":"Ther Clin Risk Manag"},{"issue":"2","key":"205_CR21","doi-asserted-by":"publisher","first-page":"185","DOI":"10.5811\/westjem.2018.11.39290","volume":"20","author":"A Kalantari","year":"2019","unstructured":"Kalantari A, Rezaie SR. Challenging the 1-h sepsis bundle. West J Emerg Med. 2019;20(2):185\u201390.","journal-title":"West J Emerg Med"},{"issue":"11","key":"205_CR22","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1097\/00005650-199711000-00002","volume":"35","author":"P Dolan","year":"1997","unstructured":"Dolan P. Modeling valuations for EuroQol health states. Med Care. 1997;35(11):1095\u2013108.","journal-title":"Med Care"},{"issue":"1","key":"205_CR23","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/j.1365-2222.1991.tb00807.x","volume":"21","author":"EF Juniper","year":"1991","unstructured":"Juniper EF, Guyatt GH. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin Exp Allergy. 1991;21(1):77\u201383.","journal-title":"Clin Exp Allergy"},{"issue":"6","key":"205_CR24","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.anai.2013.03.013","volume":"110","author":"H Nolte","year":"2013","unstructured":"Nolte H, et al. Randomized controlled trial of ragweed allergy immunotherapy tablet efficacy and safety in North American adults. Ann Allergy Asthma Immunol. 2013;110(6):450\u201356 (e4).","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"5","key":"205_CR25","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1016\/j.jaci.2013.03.019","volume":"131","author":"PS Creticos","year":"2013","unstructured":"Creticos PS, et al. Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults. J Allergy Clin Immunol. 2013;131(5):1342\u20139 (e6).","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"205_CR26","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1002\/alr.21917","volume":"7","author":"RT Crump","year":"2017","unstructured":"Crump RT, et al. Establishing utility values for the 22-item Sino-Nasal Outcome Test (SNOT-22) using a crosswalk to the EuroQol-five-dimensional questionnaire-three-level version (EQ-5D-3L). Int Forum Allergy Rhinol. 2017;7(5):480\u20137.","journal-title":"Int Forum Allergy Rhinol"},{"issue":"6","key":"205_CR27","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.jval.2017.09.017","volume":"21","author":"LA Gray","year":"2018","unstructured":"Gray LA, Alava MH, Wailoo AJ. Development of methods for the mapping of utilities using mixture models: mapping the AQLQ-S to the EQ-5D-5L and the HUI3 in patients with asthma. Value Health. 2018;21(6):748\u201357.","journal-title":"Value Health"},{"issue":"5","key":"205_CR28","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1183\/09031936.04.00013904","volume":"24","author":"V Bauchau","year":"2004","unstructured":"Bauchau V, Durham SR. Prevalence and rate of diagnosis of allergic rhinitis in Europe. Eur Respir J. 2004;24(5):758\u201364.","journal-title":"Eur Respir J"},{"issue":"4","key":"205_CR29","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1111\/all.13420","volume":"73","author":"A Muraro","year":"2018","unstructured":"Muraro A, et al. EAACI guidelines on allergen immunotherapy: executive statement. Allergy. 2018;73(4):739\u201343.","journal-title":"Allergy"}],"container-title":["PharmacoEconomics - Open"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-020-00205-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s41669-020-00205-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-020-00205-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,9]],"date-time":"2021-03-09T01:10:00Z","timestamp":1615252200000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s41669-020-00205-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,9]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["205"],"URL":"https:\/\/doi.org\/10.1007\/s41669-020-00205-y","relation":{},"ISSN":["2509-4262","2509-4254"],"issn-type":[{"value":"2509-4262","type":"print"},{"value":"2509-4254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,9]]},"assertion":[{"value":"9 March 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"K Dick is an employee of Avalon Health Economics, which received funding from ALK. Dr Briggs is a director and shareholder of Avalon Health Economics and received compensation from ALK as a consultant for this work. He has also been contracted by Eisai, Bayer, Merck, Janssen, Novartis, Sword Health, Amgen and Daiichi Sankyo and received compensation outside of the submitted work. H. Brandi is an employee of ALK.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was funded by ALK.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"All procedures performed in studies involving human participants were conducted in accordance with good clinical practice and with the internal standard operating procedures of Schering-Plough Research Institute.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statement of human rights"}},{"value":"This article does not contain any studies with animals performed by any of the authors.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Welfare of animals"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The clinical trial data that support the findings of this study are proprietary to ALK and therefore cannot be made publicly available.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}}]}}